These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
332 related articles for article (PubMed ID: 19812153)
21. Evaluation of antiviral effects of novel NS5A inhibitors in hepatitis C virus cell culture system with full-genome infectious clones. Murayama A; Fujiwara K; Yamada N; Shiina M; Aly HH; Masaki T; Muramatsu M; Wakita T; Kato T Antiviral Res; 2018 Oct; 158():161-170. PubMed ID: 30118732 [TBL] [Abstract][Full Text] [Related]
22. Distinct functions of NS5A in hepatitis C virus RNA replication uncovered by studies with the NS5A inhibitor BMS-790052. Fridell RA; Qiu D; Valera L; Wang C; Rose RE; Gao M J Virol; 2011 Jul; 85(14):7312-20. PubMed ID: 21593143 [TBL] [Abstract][Full Text] [Related]
23. In vitro resistance profile of hepatitis C virus NS5A inhibitor velpatasvir in genotypes 1 to 6. Dvory-Sobol H; Han B; Lu J; Yu M; Beran RK; Cheng G; Martin R; Svarovskaia E; Mo H J Viral Hepat; 2019 Aug; 26(8):991-1001. PubMed ID: 31009123 [TBL] [Abstract][Full Text] [Related]
24. Combination treatment with hepatitis C virus protease and NS5A inhibitors is effective against recombinant genotype 1a, 2a, and 3a viruses. Gottwein JM; Jensen SB; Li YP; Ghanem L; Scheel TK; Serre SB; Mikkelsen L; Bukh J Antimicrob Agents Chemother; 2013 Mar; 57(3):1291-303. PubMed ID: 23274664 [TBL] [Abstract][Full Text] [Related]
25. Combination therapies with NS5A, NS3 and NS5B inhibitors on different genotypes of hepatitis C virus in human hepatocyte chimeric mice. Shi N; Hiraga N; Imamura M; Hayes CN; Zhang Y; Kosaka K; Okazaki A; Murakami E; Tsuge M; Abe H; Aikata H; Takahashi S; Ochi H; Tateno-Mukaidani C; Yoshizato K; Matsui H; Kanai A; Inaba T; McPhee F; Gao M; Chayama K Gut; 2013 Jul; 62(7):1055-61. PubMed ID: 23322441 [TBL] [Abstract][Full Text] [Related]
26. Antiviral activity and resistance of HCV NS5A replication complex inhibitors. Gao M Curr Opin Virol; 2013 Oct; 3(5):514-20. PubMed ID: 23896281 [TBL] [Abstract][Full Text] [Related]
27. In vitro activity of daclatasvir on hepatitis C virus genotype 3 NS5A. Wang C; Valera L; Jia L; Kirk MJ; Gao M; Fridell RA Antimicrob Agents Chemother; 2013 Jan; 57(1):611-3. PubMed ID: 23089758 [TBL] [Abstract][Full Text] [Related]
28. Natural prevalence of NS5A polymorphisms in subjects infected with hepatitis C virus genotype 3 and their effects on the antiviral activity of NS5A inhibitors. Hernandez D; Zhou N; Ueland J; Monikowski A; McPhee F J Clin Virol; 2013 May; 57(1):13-8. PubMed ID: 23384816 [TBL] [Abstract][Full Text] [Related]
29. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Gao M; Nettles RE; Belema M; Snyder LB; Nguyen VN; Fridell RA; Serrano-Wu MH; Langley DR; Sun JH; O'Boyle DR; Lemm JA; Wang C; Knipe JO; Chien C; Colonno RJ; Grasela DM; Meanwell NA; Hamann LG Nature; 2010 May; 465(7294):96-100. PubMed ID: 20410884 [TBL] [Abstract][Full Text] [Related]
31. Design, synthesis and evaluation of novel anti-HCV molecules that deliver intracellularly three highly potent NS5A inhibitors. Boucle S; Tao S; Amblard F; Stanton RA; Nettles JH; Li C; McBrayer TR; Whitaker T; Coats SJ; Schinazi RF Bioorg Med Chem Lett; 2015 Sep; 25(17):3711-5. PubMed ID: 26099532 [TBL] [Abstract][Full Text] [Related]
32. Discovery of hepatitis C virus NS5A inhibitors as a new class of anti-HCV therapy. Lee C Arch Pharm Res; 2011 Sep; 34(9):1403-7. PubMed ID: 21975800 [TBL] [Abstract][Full Text] [Related]
33. Protease inhibitor-resistant hepatitis C virus mutants with reduced fitness from impaired production of infectious virus. Shimakami T; Welsch C; Yamane D; McGivern DR; Yi M; Zeuzem S; Lemon SM Gastroenterology; 2011 Feb; 140(2):667-75. PubMed ID: 21056040 [TBL] [Abstract][Full Text] [Related]
35. Resistance analysis of the hepatitis C virus NS5A inhibitor BMS-790052 in an in vitro replicon system. Fridell RA; Qiu D; Wang C; Valera L; Gao M Antimicrob Agents Chemother; 2010 Sep; 54(9):3641-50. PubMed ID: 20585111 [TBL] [Abstract][Full Text] [Related]
36. Inhibition of HCV replication by cyclophilin antagonists is linked to replication fitness and occurs by inhibition of membranous web formation. Madan V; Paul D; Lohmann V; Bartenschlager R Gastroenterology; 2014 May; 146(5):1361-72.e1-9. PubMed ID: 24486951 [TBL] [Abstract][Full Text] [Related]
37. Effect on hepatitis C virus replication of combinations of direct-acting antivirals, including NS5A inhibitor daclatasvir. Pelosi LA; Voss S; Liu M; Gao M; Lemm JA Antimicrob Agents Chemother; 2012 Oct; 56(10):5230-9. PubMed ID: 22850513 [TBL] [Abstract][Full Text] [Related]
38. Resensitizing daclatasvir-resistant hepatitis C variants by allosteric modulation of NS5A. Sun JH; O'Boyle DR; Fridell RA; Langley DR; Wang C; Roberts SB; Nower P; Johnson BM; Moulin F; Nophsker MJ; Wang YK; Liu M; Rigat K; Tu Y; Hewawasam P; Kadow J; Meanwell NA; Cockett M; Lemm JA; Kramer M; Belema M; Gao M Nature; 2015 Nov; 527(7577):245-8. PubMed ID: 26536115 [TBL] [Abstract][Full Text] [Related]
39. Transient replication of a hepatitis C virus genotype 1b replicon chimera encoding NS5A-5B from genotype 3a. Kylefjord H; Danielsson A; Sedig S; Belda O; Wiktelius D; Vrang L; Targett-Adams P J Virol Methods; 2014 Jan; 195():156-63. PubMed ID: 24120570 [TBL] [Abstract][Full Text] [Related]
40. Hepatitis C virus genotype 5a subgenomic replicons for evaluation of direct-acting antiviral agents. Wose Kinge CN; Espiritu C; Prabdial-Sing N; Sithebe NP; Saeed M; Rice CM Antimicrob Agents Chemother; 2014 Sep; 58(9):5386-94. PubMed ID: 24982066 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]